sapropterin has been researched along with 2019 Novel Coronavirus Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bokov, D; Dey, SK; Farasati Far, B; Javanshir, S; Kamal Abdelbasset, W; Pazoki-Toroudi, H; Seif, F; Setia Budi, H; Widjaja, G | 1 |
1 other study(ies) available for sapropterin and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Metronidazole, acyclovir and tetrahydrobiopterin may be promising to treat COVID-19 patients, through interaction with interleukin-12.
Topics: COVID-19; Cytokines; Humans; Interleukin-12; Metronidazole; Molecular Docking Simulation | 2023 |